Human T-cell leukemia virus (HTLV) type I (HTLV-I) and T-cell lymphotropic virus type III (HTLV-III/LAV) are the etiologic agents of adult T-cell leukemia-lymphoma (10, 20, 31) and acquired immune deficiency syndrome (2, 4, 11, 19, 21, 23), respectively. HTLV type II (HTLV-IT), although similar in structure to HTLV-I, was isolated from a patient with a benign T-cell variant of hairy cell leukemia (6, 12, 15) . These viruses encode genes designated tat I, tat II, and tat III, the products of which activate in trans gene expression directed by the respective long terminal repeats (LTRs) (1, 7, 9, 24, 27, 31) . In addition to an autostimulatory role that augments viral gene expression and virion production, it has been suggested that the tat gene products mediate some of the pathological effects associated with infection by these viruses (1, 26) .
To study the physiological consequence of tat gene expression, a high-efficiency vector capable of transferring these genes into cells is required. Disadvantages associated with the standard transfection methods include low efficiency of gene transfer and inability to transfect certain cell types efficiently. In this context, retroviral vectors offer several advantages, including efficient infection and predictable integration configuration (29) . Here we describe the construction and activity of Moloney murine leukemia virusbased retrovirus vectors, derivatives of the pZIPNEO vectors developed by Cepko and co-workers (5) that contain the HTLV-II and HTLV-III/LAV tat genes.
The defective retroviral vector used for these studies, pZIPNEOSV(X)1 (Fig. 1) , contains Moloney murine leukemia virus LTRs, polyadenylation signals, sequences required for reverse transcription and for encapsidation of RNA, as well as the 5' and 3' splicing signals that normally produce subgenomic env gene messenger RNA (5) . The vector also contains the bacterial gene for neomycin resistance (neo), which confers a dominant selectable resistance to the antibiotic G418 in eucaryotic cells (28) .
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The tat II gene of HTLV-II was obtained from plasmid pCATLORIIgpt (Fig. 1) . This plasmid expresses a fusion protein consisting of nine amino-terminal residues (providing the ATG initiation codon) encoded by the bacterial chloramphenicol acetyltransferase (CAT) gene and the product of the entire tat II gene, extending from the splice acceptor to the termination codon present in the 3' LTR (25) . A similar plasmid that contained the tat II gene in the antisense orientation relative to pZIPNeotatII was constructed (pZIPNeotatII-A).
The HTLV-III/LAV tat III gene was obtained from infectious proviral clone HXBC2 (Fig. 1 ) and encodes the HTLV-III/LAV associated trans-acting factor (1, 26) . The recombinant viruses were constructed as outlined in the legend to Fig. 1 . DNA was introduced into the psi 2 (ecotropic) and psi AM (amphotropic) cell lines by the calcium phosphate coprecipitation method (30) . These lines constitutively produce the murine leukemia virus proteins but cannot package the viral transcripts (8, 18) . Two days following transfection, cells were selected with the antibiotic G418 (400 ,ug/ml for fibroblast lines and 700 ,ug/ml for lymphocytes). G418-resistant clones were evident in 7 to 10 days. Evidently, insertion of the tat regions does not interfere with splicing events required for transcription of the neo gene. G418-resistant psi 2 and psi AM clones were isolated, and the virus from clones producing greater than 103 infectious units per ml was used to infect the test cells (16 1 . Construction of pZIPNeotatII and pZIPNeotatIII. The construction of the vector plasmid pZIPNEOSV(X)l has been previously described (5) . The HTLV-II tat II gene was obtained from plasmid pCATLORIIgpt. The HTLV-III/LAV tat III gene was obtained from the infectious HTLV-III/LAV proviral clone HXBC2 (8a, 26). Plasmids were constructed by standard recombinant DNA methodology (17) . Lymphoid cells were infected as described by King et al. (16) . (25) . To determine whether the tat II gene transcripts present in infected cells direct the synthesis of a functional tat product, levels of HTLV-I and HTLV-II LTR-directed gene expression were compared in uninfected and infected cells (Table 1) . In a previous study we have shown that the tat I and tat II gene products are functionally equivalent in trans-activation of HTLV-I and HTLV-II LTRs (25) . Cells were transfected with plasmids that contained the bacterial CAT gene under control of the HTLV-I LTR (pU3R-I) and the HTLV-II LTR (pU3R-II) (Fig. 3) . As controls for specificity of trans-activation, the cells were also transfected with plasmids that contained the Rous sarcoma virus LTR (RSVCAT), the HTLV-III/LAV LTR (pU3R-III), or the simian virus 40 early region (pSV2CAT) transcription regulatory sequences upstream to the CAT gene (Fig. 3) . The level of CAT activity was measured in cell extracts prepared at 48 h posttransfection. To establish a control for differences in transfection efficiencies that might be associated with the individual clones, the level of CAT activity was normalized to the activity obtained following transfection of the same cells with plasmid pSV2CAT.
The data in Table 1 and Fig. 2B (11) 6.00 a Uninfected cells and retrovirus-infected clonal cells or pools were transfected with 2 ,ug of the indicated plasmid DNA (described in the text). CAT assays were performed 48 h posttransfection as previously described (14, 24) . Reaction products were separated by ascending thin-layer chromatography and quantitated by liquid scintillation counting of the spots cut from the thin-layer chromatographic plates. pU3R-III. This plasmid contains HTLV-III/LAV LTR sequences 5' to the CAT gene (27) . Previous studies have shown that the tat III gene product activates in trans gene expression directed by the HTLV-III/LAV LTR (26, 27) . The level of HTLV-III/LAV LTR-directed gene expression was dramatically increased in ZIPNeotatIII-infected HeLa cells compared with uninfected cells (Table 1; Fig.  2B ). For example, relative to pSV2CAT, gene expression directed by plasmid pU3R-III was increased between 760 and 1,100 times depending on the clone tested. In ZIPNeotatIII-infected Raji cells, HTLV-III/LAV LTRdirected gene expression was increased approximately 2,000-fold relative to control Raji cells. The level of CAT activity was increased by 6.5-to 23-fold in infected NIH 3T3 cells. The levels of Rous sarcoma virus LTR-and HTLV-I LTR-directed CAT gene expression were the same in infected and uninfected cells.
From these experiments we conclude that infection of cells with the ZIPNeotatIII and ZIPNeotatII viruses leads to the synthesis of functional tat gene products. Moreover, the level of trans-activation in many of the infected cells approximates the level of trans-activation obtained with the respective HTLV infection.
The results reported here demonstrate that use of the recombinant retroviruses that express the tat II and tat III genes permits efficient transfer of these genes into a wide variety of cell types, including human lymphoid lines. 
